Introduction:

Anticoagulation is essential for treating thromboembolic diseases and preventing complications associated with pathologies such as atrial fibrillation. However, it carries a significant risk of bleeding, which highlights the importance of reversal agents use. In Colombia, scientific evidence on these therapies is limited.

Objective:

To implement the Colombian Registry of Anticoagulation Clinics (RECCANT) and the Colombian Registry of Anticoagulation Clinics and and the Use of Reversal Agents (RECCANT-AR), which aim to fill this information gap by providing robust and representative data on these patients.

Method:

RECCANT is an observational, analytical, prospective, and multicenter study that includes patients over 18 years of age with an indication for anticoagulant management for at least 3 months. RECCANT-AR is an observational, analytical, ambispective, and multicenter study that includes patients over 18 years of age requiring reversal agents due to significant bleeding or the need for urgent or priority invasive procedures. Sociodemographic, clinical, and therapeutic data are collected using he electronic platform REDCap (Research Electronic Data Capture) to ensure information security and confidentiality.

Results:

RECCANT and RECCANT-AR are established as the first national registries focused on characterizing anticoagulated patients and those requiring reversal agents.

Conclusions:

RECCANT and RECCANT-AR are essential for addressing the knowledge gap regarding anticoagulation and the use of reversal agents in Colombia. By providing precise and detailed information, these registries will improve understanding of patient profiles, identify national patterns, and support the development of standardized strategies to enhance care and clinical outcomes in the country.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )